The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.00
Bid: 51.00
Ask: 53.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.922%)
Open: 52.00
High: 52.00
Low: 52.00
Prev. Close: 52.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Admission Application & Exercise of Options

21 Mar 2023 07:00

RNS Number : 5850T
Cambridge Cognition Holdings PLC
21 March 2023
 

21 March 2023

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Admission Application

 

Exercise of Options and PDMR Dealing

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that an application has been made to the London Stock Exchange for a block admission of 1,000,000 ordinary shares of £0.01 each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission"). 

 

The Block Admission relates to Ordinary Shares that will be issued from time to time in accordance with the exercise of options previously granted by the Company. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.

 

It is expected that the Block Admission will become effective on or around 23 March 2023.

 

In addition, the Company has issued and allotted 199,701 new Ordinary Shares in the share capital of the Company following the exercise of 222,820 options on 16 March 2023 ("Option Exercise"). Of the options exercised, 90,000 were exercised utilising the net cashless exercise feature, resulting in 23,119 options being surrendered to the Company. The options were exercised pursuant to the Cambridge Cognition Holdings 2013 EMI Share Option Plan. The new Ordinary Shares will be admitted to trading pursuant to the Block Admission.

 

Included in the exercise of options were options over 119,534 Ordinary Shares held by PDMRs of the Company as detailed in the table below:

 

Director/ PDMR

Position

Existing interest in Ordinary Shares

Number of Options over Ordinary Shares exercised

Resultant interest in Ordinary Shares

Rollover options remaining after exercise

Ricky Dolphin

Chief Technology Officer

-

119,534

119,534

-

 

 

Total voting rights

 

Following the issue of the new Ordinary Shares pursuant to the Option Exercise, the total number of voting rights of the Company will be 34,815,389. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cambridge Cognition Holdings Plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

Tel: 020 3903 7715 

 

 

IFC Advisory Ltd (Financial PR and IR) 

Tim Metcalfe / Graham Herring / Zach Cohen 

 

Tel: 020 3934 6630 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ricky Dolphin

2

Reason for the notification

a)

Position/status

Chief Technology Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.01p each

 

GB00B8DV9647

b)

Nature of the transaction

Exercise of Share Options

c)

Price(s) and volume(s)

   Price(s)

Volume(s)

a) £0.01

b) £0.70

c) £0.28

a) 19,721

b) 1,600

c) 98,213

d)

Aggregated information

- Aggregated volume

- Price

 

119,534

£0.24

e)

Date of the transaction

20 March 2023

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEPPUWAWUPWGMU
Date   Source Headline
23rd Apr 20247:00 amRNSCOG spin-out Monument Therapeutics accesses £1.5m
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.